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Hippocampal glutamate-glutamine (Glx) in adults
with Down syndrome: a preliminary study using
in vivo proton magnetic resonance spectroscopy
(1H MRS)
Giles MY Tan1,2*, Felix Beacher1, Eileen Daly1, Jamie Horder1, Verinder Prasher3, Maria-Luisa Hanney4, Robin Morris5,
Simon Lovestone6, Kieran C Murphy7, Andrew Simmons8,9 and Declan GM Murphy1,9
Abstract
Background: Down syndrome (DS), or trisomy 21, is one of the most common autosomal mutations. People with
DS have intellectual disability (ID) and are at significantly increased risk of developing Alzheimer’s disease (AD). The
biological associates of both ID and AD in DS are poorly understood, but glutamate has been proposed to play a
key role. In non-DS populations, glutamate is essential to learning and memory and glutamate-mediated excitotoxicity
has been implicated in AD. However, the concentration of hippocampal glutamate in DS individuals with and without
dementia has not previously been directly investigated. Proton magnetic resonance spectroscopy (1H MRS) can be
used to measure in vivo the concentrations of glutamate-glutamine (Glx). The objective of the current study was to
examine the hippocampal Glx concentration in non-demented DS (DS-) and demented DS (DS+) individuals.
Methods: We examined 46 adults with DS (35 without dementia and 11 with dementia) and 39 healthy controls (HC)
using 1H MRS and measured their hippocampal Glx concentrations.
Results: There was no significant difference in the hippocampal Glx concentration between DS+ and DS-, or between
either of the DS groups and the healthy controls. Also, within DS, there was no significant correlation between
hippocampal Glx concentration and measures of overall cognitive ability. Last, a sample size calculation based
on the effect sizes from this study showed that it would have required 6,257 participants to provide 80%
power to detect a significant difference between the groups which would indicate that there is a very low
likelihood of a type 2 error accounting for the findings in this study.
Conclusions: Individuals with DS do not have clinically detectable differences in hippocampal Glx concentration.
Other pathophysiological processes likely account for ID and AD in people with DS.
Keywords: Down syndrome, Intellectual disability, Alzheimer’s disease, Dementia, Magnetic resonance spectroscopy,
1H MRS, Hippocampus, Glutamate-glutamine (Glx)
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Background
Down syndrome (DS) is one of the most common chromo-
somal disorders and is caused by trisomy 21 or a transloca-
tion involving chromosome 21 [1]. A prominent feature of
DS is intellectual disability (ID) and there is an increased
risk of developing Alzheimer’s disease (AD) [2]. For
example, it has been estimated that the prevalence of AD
in DS increases dramatically from 11% between ages 40 to
49 to as high as 77% between 60 and 69 [3-5].
The underlying cause(s) for both the ID and AD is likely
to be multifactorial. For instance, it has been hypothesised
that in the DS brain, the presence of an extra copy of the
amyloid precursor protein (APP) gene (which is localised
to chromosome 21) leads to abnormalities in amyloid
precursor protein processing in neuronal membranes
and subsequently to amyloid plaques and AD [6]. In
addition, reduced levels of serotonin (5HT) and gamma-
aminobutyric acid (GABA) have been observed in foetal
DS brains [7]. Further, it has been reported that in a DS
mouse model, the selective serotonin reuptake inhibitor
fluoxetine normalises hippocampal neurogenesis and
performance on a hippocampus-dependent memory task
[8]—whereas excessive GABA-mediated inhibition im-
pairs the induction of long-term potentiation (LTP) and
memory processes in the same region [9]. We previously re-
ported our findings of myo-inositol (mI), N-acetylaspartate
(NAA), choline-containing compounds (Cho) and creatine
and phosphocreatine (Cr + Pr) from the current study
sample in an earlier paper which showed that adults with
DS have a significantly increased hippocampal concentra-
tion of myo-inositol as compared to healthy controls [10]
and that this is associated with reduced cognitive ability.
Increased concentration of myo-inositol within individuals
with DS may also be associated with increased risk for
AD [11]. Hence, there is increasing evidence that a num-
ber of neurochemical systems likely contribute to the DS
cognitive phenotype—but there have been relatively few
studies on the putative role of glutamate within individ-
uals with DS.
Normal cognitive function (including attention, learn-
ing, memory and executive processes) is supported by a
number of neurotransmitters—central to which is the
glutamatergic system [12]. Glutamate is the primary ex-
citatory neurotransmitter in the brain and is involved in
synaptic transmission, plasticity and excitotoxicity [13].
Enhanced glutamate release from presynaptic neurons
and subsequent activation of postsynaptic alpha-amino-
3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)
and N-methyl-D-aspartate (NMDA) glutamate receptors
are crucial for LTP [14,15] and successful performance of
numerous higher cognitive functions—including memory
and learning [16,17]. Also, it has been suggested that
within the non-DS population, glutamate-mediated exci-
totoxicity contributes to the neurodegeneration and
cognitive dysfunction typically observed in people with
AD [18-21].
The importance of this neurotransmitter pathway in
non-DS people with AD is further supported by evidence
from clinical trials in these populations which showed the
efficacy of drugs that target glutamatergic neurotransmis-
sion. For example, it has been reported that meman-
tine (an NMDA receptor antagonist) reduces hippocampal
glutamate concentration [22] and improves the behav-
ioural, cognitive and functional symptoms in people with
AD [23]. Therefore, there is evidence that reduction in
hippocampal glutamate concentrations is associated with
improved cognitive function by modulating glutamatergic
neurotransmission and reducing excitotoxicity in non-DS
people with AD.
Further, murine models of DS suggest 1) that there is
an imbalance between hippocampal inhibitory and exci-
tatory inputs [9,24], 2) there are changes in the levels of
the glutamate transporter and vesicular glutamate trans-
porter 1 (VGLUT1) [25] and 3) that there are impairments
in signalling mechanisms downstream of the NMDA
receptor [26]. Therefore, based on the above considered
evidence, it is possible that abnormalities in glutamate me-
tabolism may partly account for both the ID and increased
risk for AD in people with DS.
There is initial indirect evidence (from studies of plate-
lets and fibroblasts) that glutamate uptake may be signifi-
cantly decreased in DS individuals [27]. There have also
been a small number of postmortem studies. For instance,
some have reported no difference in glutamine or glutam-
ate concentration in the frontal lobes of foetal DS brains
as compared to controls [7]. In contrast, some (but not
all) autopsy studies of adult DS brains reported decreased
glutamate levels in the hippocampus [28] or no differences
in the temporal lobes [29] or frontal lobes [30]. These
studies were important first steps—but postmortem stud-
ies have inherent (and significant) limitations for measur-
ing glutamate, and this prior work was confounded by
medication effects. Also, to date, there are few studies that
have directly examined in vivo brain glutamate in DS.
Proton magnetic resonance spectroscopy
Proton magnetic resonance spectroscopy (1H MRS) can be
used to measure brain concentrations of glutamate-glutamine
(Glx), mI, NAA, Cho and Cr + PCr [31,32]. In excitatory
neurotransmission, glutamate is released into the synaptic
cleft and is then rapidly removed by uptake into astrocytes
(where it is converted into glutamine) and subsequently
transported back to the presynaptic neuron for reconver-
sion to glutamate [33,34]. The Glx signal on 1H MRS can
therefore be used as a measure for central glutamatergic
neurotransmission—albeit without sufficient resolution to
determine which particular component of the Glx cycle
is abnormal.
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There are only two prior 1H MRS studies of Glx in
people with DS. These reported a significant decrease in
Glx concentration within DS frontal lobe [35]—but no
difference in the temporal lobe [36]. Those two studies
were valuable first steps, but they only included children
and did not examine brain regions most implicated in
AD. Therefore, to explore the putative role that the glu-
tamatergic neurotransmitter system plays in ID and risk
of AD in DS, in vivo studies of adults are required.
The hippocampus may be of particular relevance in
people with DS as its volume has been reported to be
disproportionately reduced ([37,38] and see review [39]),
and it is the brain region most vulnerable to the neuro-
pathological changes of AD [40,41]. To the best of our
knowledge, there are no studies to date that have evalu-
ated the in vivo concentrations of hippocampal Glx in
DS adults. Therefore, given the potential contributory
role of abnormalities in glutamatergic neurotransmission
to both ID and AD in people with DS, we investigated
the hippocampal concentration of Glx in DS adults with
(DS+) and without (DS-) dementia using 1H MRS.
Methods
Participants
We included 85 adults: 46 DS individuals (35 DS-
and 11 DS+) and 39 healthy controls (Table 1). Indi-
viduals with DS were recruited from cohorts in London,
Birmingham and Newcastle upon Tyne, England. Karyo-
typing was used to assess the DS status in all participants.
Dementia status was assessed using International Statis-
tical Classification of Diseases, 10th Revision research cri-
teria [42].
All participants underwent standard physical, neuro-
logical and psychiatric screening, including routine
blood tests (e.g. renal and liver function tests, red blood
cell count and thyroid function tests) and clinical mag-
netic resonance imaging. We excluded people with a
clinically detectable physical or psychiatric disorder af-
fecting brain function (e.g. hypertension), a known his-
tory of birth trauma or head injury, or with an abnormal
clinical magnetic resonance image (for example, as indi-
cated by the presence of significant white matter hyper-
intensities). None of the participants were taking
psychotropic medication at the time of the study. The
project was approved by Multi-Centre Research Ethics
Committee (MREC) and Local Research Ethics Commit-
tees (LREC), and after complete description of the study
to the participants and their identified carers, written in-
formed consent was obtained from them or if this was
not possible, assent was obtained from their identified
carers.
1H MRS data acquisition and analysis
1H MRS protocol
The subjects were scanned using a 1.5 Tesla GE NV/i
Signa MR System (General Electric, Milwaukee, WI,
USA) at the Maudsley Hospital, London. 3D T1-
weighted volume images were acquired in the axial plane
Table 1 Demographic, MRI and 1H MRS characteristics by group
Non-demented DS (DS-) Demented DS (DS+) Healthy controls (HC) Significance
N = 85 n = 35 n = 11 n = 39
Demographics, mean (percent)
Male no. 26 (74%) 6 (55%) 24 (62%) p = 0.358a
Age, mean (SD) 35 (12) 52 (6) 35 (12) p < 0.001b
Cognitive measures
CAMCOG (total) score 56 (22) 32 (21) 119 (3) p < 0.001b
CAMCOG (short-term memory) score 12 (7) 5 (4) 22 (2) p < 0.001b
MRI VOI proportions
Grey proportion (average R and L) 0.76 (0.07) 0.75 (0.11) 0.72 (0.08) p = 0.187b
White proportion (average R and L) 0.24 (0.07) 0.25 (0.11) 0.28 (0.08) p = 0.187b
Mean CSF (R) 0.13 (0.07) 0.15 (0.04) 0.07 (0.04) p = 0.000b
Mean CSF (L) 0.10 (0.07) 0.17 (0.09) 0.07 (0.04) p = 0.006b
Mean metabolite concentration
Glx (R hippocampus) 38.89 (6.13) 41.04 (4.16) 38.49 (7.03) p = 0.309c
Glx (L hippocampus) 36.51 (5.25) 36.56 (7.20) 36.59 (5.72) p = 0.955c
Glx (average of R and L) 38.14 (5.61) 38.41 (4.71) 37.57 (5.16) p = 0.853c
L left, R right, CAMCOG Cambridge Cognitive Examination, VOI volume of interest.
aChi-square.
bANOVA.
cANCOVA (covaried with age).
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with 1.5-mm contiguous sections using acquisition pa-
rameters chosen using a contrast simulation tool [43].
Repetition time (TR) was 13.8 ms, inversion time (TI)
450 ms, echo time (TE) 2.8 ms and the flip angle was 20°
with one data average and a 256 × 256 × 124 voxel matrix.
Acquisition time was 6 min, 27 s.
1H MRS voxels of interest measuring 20 × 20 × 15 mm3
(6 ml) were defined in standard locations in the left and
right hippocampi using a previously published method
[44,45]. We chose hippocampal regions of interest as they
were of particular relevance in DS and one of the earliest
sites of change in AD. The anterior location of the voxel
was defined as the coronal slice where the amygdala dis-
appeared, extending posteriorly 20 mm and so covering
the bulk of the hippocampus (Figure 1). The hippo-
campal volume of interest contained both grey and white
matter and included some superior medial portions of
the parahippocampal gyrus and the posterior portion
of the amygdala.
A point resolved spectroscopy (PRESS) pulse sequence
(TE 35 ms, TR 1500 ms, 256 data averages and 2,048
points) with automated shimming and water suppression
and excellent reproducibility [46] was used to obtain spec-
tra from each voxel after CHESS water suppression with
high signal-to-noise ratio and clearly resolved NAA, Cho,
mI, Cr + PCr and Glx peaks among other metabolites.
Non-water-suppressed data were also collected for water
referencing, but data was not collected to measure metab-
olite T1 and T2 relaxation times for individual subjects
due to the limited tolerance of DS subjects for MRI scan-
ning. Results are expressed as relaxation time corrected
ratios to unsuppressed water. Not all subjects had spectral
data from both left and right hippocampi. No significant
differences were found in the metabolite content between
the right and the left side of the hippocampus. Therefore,
we averaged the metabolite measures from the left and
right hippocampi from the subjects which had data from
both hemispheres.
1H MRS data analysis
Differences in proportions of white and grey matter in
the 1H MRS voxels may confound group differences in
metabolite concentrations. Thus, to ensure that differ-
ences in tissue composition did not account for meta-
bolic differences between subject groups, we segmented
the SPGR volumes using Statistical Parametric Mapping
(SPM) software (http://www.fil.ion.ucl.ac.uk/spm) to de-
termine the percentage of grey matter, white matter and
CSF within the MRS voxels after quality control of the
images as described previously [47,48]. The position of
the 1H MRS voxels relative to the segmented 3D dataset
was determined automatically using an in-house soft-
ware. T1 and T2 corrections were applied for each me-
tabolite using literature values [49].
Spectra were processed using LCModel [50], and me-
tabolite concentrations were automatically corrected for
CSF contamination of the voxel by dividing by the tissue
fraction of the MRS voxel determined using SPM. These
corrected concentrations were then calibrated to abso-
lute molar units with respect to a phantom of known
concentration, which was scanned in the same scanning
session as the subject, using a PRESS acquisition with
the same TE and TR.
Cognitive assessment
Cognitive ability was measured using the Cambridge
Cognitive Examination (CAMCOG) [51,52]. The CAMCOG
has been validated for use with adults with DS [53] and
provides a measure of general cognitive function, includ-
ing measures of episodic memory (which is associated
with hippocampal function), orientation, language, atten-
tion, praxis and executive function. The CAMCOG, devel-
oped originally to measure cognitive functioning in people
with mild to moderate dementia, is less subject to floor
effects and so found to be also appropriate for people
with DS. For each participant, neuropsychological testing
was completed within 6 months of scanning.
Statistical analysis
Statistical analysis was carried out using SPSS (SPSS
18.0 for Windows; SPSS Inc., Chicago, IL, USA). Com-
parisons between age and 1H MRS Glx concentrations
between the groups were made using univariate general
linear models (GLM). Differences in gender distribution
were tested for using a chi-squared test. Group differ-
ences in Glx concentrations were tested with one-way
Figure 1 Coronal T1-weighted magnetic resonance image
illustrating the location of the 1H MRS voxels in the left
and right hippocampi.
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analysis of variance (ANOVA), with group as the between-
subject factor. There were no significant interactions be-
tween the side from which 1H MRS Glx concentrations
were measured (left or right hippocampus) or gender and
group. To verify that voxel composition was not obscuring
group differences, we performed an ANOVA with cor-
rected Glx as the dependent variable, Group (DS-, DS+,
HC) and Side (left vs. right) as a between-subject factor
and covariates being voxel grey, white and CSF proportion.
In this analysis, neither Group nor Group × Side were
significant predictors of estimated Glx (p = 0.199 and
p = 0.550) indicating that even controlling for voxel com-
position, there was no group difference in Glx in either
left or right hippocampus. Therefore, mean hippocampal
Glx concentrations were considered in the analysis with
age used as a covariate.
For each of the groups, the relationship between hippo-
campal Glx concentrations and cognitive ability and mem-
ory (measured by the CAMCOG total and short-term
memory scores) was examined using Pearson’s product–
moment correlation. Level of statistical significance was de-
fined as p < 0.05 (two tailed). Power calculations were
performed using the mean Glx concentration differences
between the groups in this study on G*Power version 3.1.5.
Results
The results are summarised in Table 1 and Figure 2. The
DS+ group were older than both the DS- and healthy
control groups. Therefore, age was added as a covariate
in the analyses. As expected, the groups also differed in
their CAMCOG (total cognition and short-term mem-
ory) scores—with the demented DS+ group having the
lowest scores and the HC having the highest.
Grey and white matter composition of the MRS voxels
did not differ between the groups, although there were
differences between the groups for CSF composition.
Overall, we found no significance between group differences
in Glx concentrations. Furthermore, there was no correl-
ation between hippocampal Glx concentration and cognitive
ability and memory as measured by the CAMCOG (total
and short-term memory) scores in either of the DS groups
(see Table 2).
Due to our relatively small sample size of DS+, it is
possible that we were underpowered to detect differ-
ences. Hence, we carried out a power analysis. This
showed that it would have required 6,257 participants to
provide 80% power to detect a significant difference in
Glx between the groups at p < 0.05 which would indicate
a very low likelihood of a type 2 error accounting for
our findings.
Discussion
Hippocampal Glx in DS and when compared with the
general population
We found no significant between-group differences in
hippocampal Glx concentration. The Glx findings in our
Figure 2 Scatter plot of average Glx concentrations of both hippocampi for all groups. No significant differences across groups (p = 0.853).
Glx glutamate-glutamine, DS- non-demented Down syndrome subjects, DS+ demented Down syndrome subjects, HC healthy controls. Note: horizontal
bars represent the means for each group.
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study are consistent with (and extends into demented
individuals) 1) an earlier 1H MRS study of DS children
that reported no differences in temporal lobe Glx concen-
tration [36] and 2) postmortem studies of adult DS brains
that had not detected any increase in temporal lobe glu-
tamate [29]. Hence, our findings suggest that the hippo-
campal glutamatergic neurotransmitter system (at least as
measured using Glx at 1.5 Tesla) is not significantly dys-
regulated in people with DS—and so is not the main cause
for the ID (or AD) typically found in the disorder.
Other factors, therefore, most likely play a greater role.
These may include dysregulation of acetylcholine (ACh)
[54], dopamine [55], GABA [56] and serotonin (5-HT)
[57]; and/or brain metabolites such as mI [10]. ACh has
long been known to be a critical mediator of learning
and memory [58], and cholinergic neurons are particu-
larly affected in AD [54]. Dopamine [55] and GABA
modulate memory, and drugs that act as inverse agonists
at the GABA(A) receptor have shown promise in enhan-
cing memory function [56]. mI is elevated in the hippo-
campus of DS- adults and is negatively correlated with
their cognitive ability [10] and further increased in DS+
individuals [11].
Hippocampal Glx in demented DS+ versus AD in the
general population
In this study, we did not find any differences in hippocam-
pal Glx concentration between DS+ individuals when
compared to either their DS- counterparts or healthy con-
trols. The DS+ group were significantly older than the
DS- and HC groups.
To the best of our knowledge, there are no previous
studies that have examined hippocampal Glx in people
with DS and AD. Our findings (albeit in a limited sam-
ple) are consistent with some (but not all) 1H MRS stud-
ies of AD in the general population. For instance, some
reported no differences in the Glx concentration of tem-
poroparietal grey matter between AD individuals and
healthy controls [59], whereas others reported decreased
glutamate in the right hippocampus [60]. Thus, the hip-
pocampal metabolic changes in people with DS and AD
may differ from those of non-DS people with AD.
However, our initial evidence taken together with the
work of others suggests that the situation may be different
in people with DS. For instance, two recent randomised
double-blind placebo-controlled trials which investigated
the efficacy of memantine in DS people found limited ef-
fect of treatment with memantine on cognitive or func-
tional outcomes. Boada et al. compared the effect of
16-week treatment with either memantine or placebo on
cognitive and adaptive functions of 40 young adults with
DS and found no significant differences between the
memantine and placebo groups on the two primary out-
come measures involving episodic memory [61]. In the
study by Hanney et al. which compared adults with DS
with and without dementia and involved 88 patients re-
ceiving memantine and 85 patients receiving placebo
showed that both groups declined in cognitive and func-
tional ability but rates did not differ between groups for
any cognitive or functional outcomes at 52 weeks of treat-
ment [62]. Therefore, in people with DS, dysregulation of
glutamatergic neurotransmission and related glutamate-
mediated excitotoxicity may not be the major pathway for
the development of either ID or AD. This has implications
for the development of new treatments.
Various risk factors and hypotheses for the pathogen-
esis of AD in DS have been proposed [63] including the
role of β-amyloid accumulation in the DS brain [6].
However, a recent in vivo study using positron emission
tomography (PET) showed that DS- individuals have
comparable concentrations of β-amyloid in the brain as
compared with non-DS people with AD [64] and would
suggest that there are factors other than β-amyloid load-
ing which are important for the development of AD in
people with DS.
These other factors may include apolipoprotein E ε4
allele [65], extended tau haplotype [66], dual-specificity
tyrosine-regulated kinase 1A (DYRK1A) and calcipressin
[67], tetranucleotide repeat in intron 7 of the APP [68],
estradiol [69], Cu/Zn superoxide dismutase (SOD1) [70],
neuroinflammation [71] and serotonergic dysfunction [8,72].
In particular, mI which has been associated with dementia
in the general population [73] and may also have particu-
lar relevance in people with DS as the Na+/myo-inositol
co-transporter gene (SCL5A3) located on chromosome 21
[74] has been shown in our previous work to be increased
in the hippocampus of DS- [10] and further increased in
DS+ [11] may point to a potential role of mI in the cas-
cade of events that lead to AD in people with DS.
Limitations
Our study had a relatively small sample size, and we in-
cluded relatively few demented DS+ participants. However,
due to the small differences between the groups, it would
have required an unrealistically large number of partici-
pants in the study to show an effect. A sample size calcula-
tion based on the effect sizes from this study showed that
it would have required 6,257 participants to provide 80%
power to detect a significant difference between the
groups. People with DS are a difficult population to recruit
Table 2 Correlation of cognitive measures with mean
hippocampal Glx concentrations for each group
Non-demented
DS (DS-)
Demented
DS (DS+)
CAMCOG (total) score r = 0.13 (p = 0.464) r = −0.225 (p = 0.715)
CAMCOG (short-term
memory) score
r = 0.123 (p = 0.497) r = −0.296 (p = 0.569)
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to studies, and they all have ID and can have difficulty
tolerating the demands of the scanning procedure and
cognitive assessments. Furthermore, the participants in
our study were not medicated or sedated prior to their
brain scans to facilitate the scan procedure.
The study was conducted at relatively low field strength
(1.5 T), and glutamate was expressed as Glx rather than as
glutamate and glutamine separately. Glutamate, glutamine
and GABA exist in a metabolite shuttle known as the glu-
tamate/GABA-glutamine cycle. Measuring Glx on its own
may not have detected changes in the metabolite shuttle
as GABA could not be accurately measured at low field
strength. It is possible that Glx metabolite changes may
have occurred in brain regions that were not examined in
this study, but the hippocampus was chosen due to its
known involvement in memory and early involvement in
AD. We did not examine other brain regions critical to
higher cognitive function owing to limitations in patient
compliance and time constraints. Despite that, we man-
aged to scan a sizeable number of non-demented DS par-
ticipants in this study and did not find any differences in
Glx concentration compared to healthy controls. We have
previously reported differences in myo-inositol concen-
tration in a similar number of participants which would
indicate that even if there were differences in Glx concen-
trations between the groups, these differences are much
less pronounced than those affecting myo-inositol.
Future studies involving larger numbers of DS+ partici-
pants, using higher field strength 1H MRS and using
multi-voxel 1H MRS approaches will allow better spectral
segregation of glutamate and glutamine and measurement
of GABA as well as the examination of other regions of
the brain critical to higher cognitive function.
Conclusions
We found no evidence that DS individuals (with or with-
out dementia) have significant dysregulation of gluta-
matergic neurotransmission. Other factors may be more
crucial in the development of both ID and AD in people
with DS.
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